Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68


Characterization of human respiratory syncytial virus (RSV) isolated from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during 2015-2017.

Liu H, Lu B, Tabor DE, Tovchigrechko A, Wilkins D, Jin H, Madhi SA, Soofie N, Esser MT, Nunes MC.

Influenza Other Respir Viruses. 2020 Mar 3. doi: 10.1111/irv.12727. [Epub ahead of print]


Associations of pathogen-specific and host-specific characteristics with disease outcome in patients with Staphylococcus aureus bacteremic pneumonia.

Sharma-Kuinkel BK, Tkaczyk C, Bonnell J, Yu L, Tovchigrechko A, Tabor DE, Park LP, Ruffin F, Esser MT, Sellman BR, Fowler VG Jr, Ruzin A.

Clin Transl Immunology. 2019 Jul 19;8(7):e01070. doi: 10.1002/cti2.1070. eCollection 2019.


Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins.

Schepp RM, de Haan CAM, Wilkins D, Layman H, Graham BS, Esser MT, Berbers GAM.

mSphere. 2019 Apr 24;4(2). pii: e00236-19. doi: 10.1128/mSphere.00236-19.


Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults.

Weinberg A, Lambert SL, Canniff J, Yu L, Lang N, Esser MT, Falloon J, Levin MJ.

Hum Vaccin Immunother. 2019;15(10):2466-2474. doi: 10.1080/21645515.2019.1589282. Epub 2019 Jun 3.


Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17.

Bin Lu, Liu H, Tabor DE, Tovchigrechko A, Qi Y, Ruzin A, Esser MT, Jin H.

Sci Rep. 2019 Mar 7;9(1):3898. doi: 10.1038/s41598-019-40387-y.


HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.

Shata MTM, Abdel-Hameed EA, Rouster SD, Yu L, Liang M, Song E, Esser MT, Shire N, Sherman KE.

Pathog Immun. 2019;4(1):39-65. doi: 10.20411/pai.v4i1.267. Epub 2019 Feb 13.


Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure.

Falsey AR, Walsh EE, Esser MT, Shoemaker K, Yu L, Griffin MP.

J Med Virol. 2019 Jan;91(1):65-71. doi: 10.1002/jmv.25285. Epub 2018 Sep 24.


Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States.

Ruzin A, Pastula ST, Levin-Sparenberg E, Jiang X, Fryzek J, Tovchigrechko A, Lu B, Qi Y, Liu H, Jin H, Yu L, Hackett J, Villafana T, Esser MT.

PLoS One. 2018 Jul 24;13(7):e0200319. doi: 10.1371/journal.pone.0200319. eCollection 2018.


Generalized ROC methods for immunogenicity data analysis of vaccine phase I studies in a seropositive population.

Yu L, Esser MT, Falloon J, Villafana T, Yang H.

Hum Vaccin Immunother. 2018;14(11):2692-2700. doi: 10.1080/21645515.2018.1489191. Epub 2018 Jul 12.


Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897.

Zhu Q, Lu B, McTamney P, Palaszynski S, Diallo S, Ren K, Ulbrandt ND, Kallewaard N, Wang W, Fernandes F, Wong S, Svabek C, Moldt B, Esser MT, Jing H, Suzich JA.

J Infect Dis. 2018 Jul 13;218(4):572-580. doi: 10.1093/infdis/jiy189.


Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against Staphylococcus aureus alpha toxin.

Ruzin A, Wu Y, Yu L, Yu XQ, Tabor DE, Mok H, Tkaczyk C, Jensen K, Bellamy T, Roskos L, Esser MT, Jafri HS.

Clin Transl Immunology. 2018 Jan 23;7(1):e1009. doi: 10.1002/cti2.1009. eCollection 2018.


Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.

Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, Dubovsky F, Griffin MP.

Pediatr Infect Dis J. 2018 Sep;37(9):886-892. doi: 10.1097/INF.0000000000001916.


Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations.

Wu Y, Liu X, Akhgar A, Li JJ, Mok H, Sellman BR, Yu L, Roskos LK, Esser MT, Ruzin A.

Infect Immun. 2018 Feb 20;86(3). pii: e00671-17. doi: 10.1128/IAI.00671-17. Print 2018 Mar.


An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.

Falloon J, Yu J, Esser MT, Villafana T, Yu L, Dubovsky F, Takas T, Levin MJ, Falsey AR.

J Infect Dis. 2017 Dec 12;216(11):1362-1370. doi: 10.1093/infdis/jix503.


Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay.

Shambaugh C, Azshirvani S, Yu L, Pache J, Lambert SL, Zuo F, Esser MT.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00225-17. doi: 10.1128/CVI.00225-17. Print 2017 Dec.


Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.

Falloon J, Talbot HK, Curtis C, Ervin J, Krieger D, Dubovsky F, Takas T, Yu J, Yu L, Lambert SL, Villafana T, Esser MT.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00157-17. doi: 10.1128/CVI.00157-17. Print 2017 Sep.


Passive and active immunization against respiratory syncytial virus for the young and old.

Villafana T, Falloon J, Griffin MP, Zhu Q, Esser MT.

Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1333425. Epub 2017 Jun 7. Review.


Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.

Griffin MP, Khan AA, Esser MT, Jensen K, Takas T, Kankam MK, Villafana T, Dubovsky F.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01714-16. doi: 10.1128/AAC.01714-16. Print 2017 Mar.


Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.

Yu XQ, Robbie GJ, Wu Y, Esser MT, Jensen K, Schwartz HI, Bellamy T, Hernandez-Illas M, Jafri HS.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01020-16. doi: 10.1128/AAC.01020-16. Print 2017 Jan.


The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.

François B, Chastre J, Eggiman P, Laterre PF, Torres A, Sanchez M, Esser MT, Bishop B, Bonten M, Goosens H, Jafri HS.

Clin Infect Dis. 2016 Aug 15;63 Suppl 2:S46-51. doi: 10.1093/cid/ciw245. Review.


Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893.

Tabor DE, Yu L, Mok H, Tkaczyk C, Sellman BR, Wu Y, Oganesyan V, Slidel T, Jafri H, McCarthy M, Bradford P, Esser MT.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5312-21. doi: 10.1128/AAC.00357-16. Print 2016 Sep.


A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.

Falloon J, Ji F, Curtis C, Bart S, Sheldon E, Krieger D, Dubovsky F, Lambert S, Takas T, Villafana T, Esser MT.

Vaccine. 2016 May 27;34(25):2847-54. doi: 10.1016/j.vaccine.2016.04.002. Epub 2016 Apr 19.


Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus.

Maifeld SV, Ro B, Mok H, Chu M, Yu L, Yamagata R, Leonardson T, Chio V, Parhy B, Park S, Carlson M, Machhi S, Ulbrandt N, Falsey AR, Walsh EE, Wang CK, Esser MT, Zuo F.

PLoS One. 2016 Apr 12;11(4):e0153019. doi: 10.1371/journal.pone.0153019. eCollection 2016.


Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques.

Patton K, Aslam S, Shambaugh C, Lin R, Heeke D, Frantz C, Zuo F, Esser MT, Paliard X, Lambert SL.

Vaccine. 2015 Aug 26;33(36):4472-8. doi: 10.1016/j.vaccine.2015.07.025. Epub 2015 Jul 20.


Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia.

Sharma-Kuinkel BK, Wu Y, Tabor DE, Mok H, Sellman BR, Jenkins A, Yu L, Jafri HS, Rude TH, Ruffin F, Schell WA, Park LP, Yan Q, Thaden JT, Messina JA, Fowler VG Jr, Esser MT.

J Clin Microbiol. 2015 Jan;53(1):227-36. doi: 10.1128/JCM.02023-14. Epub 2014 Nov 12.


Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.

Patton K, Aslam S, Lin J, Yu L, Lambert S, Dawes G, Esser MT, Woo J, Janetzki S, Cherukuri A.

Clin Vaccine Immunol. 2014 May;21(5):628-35. doi: 10.1128/CVI.00736-13. Epub 2014 Feb 26.


Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.

Malkin E, Yogev R, Abughali N, Sliman J, Wang CK, Zuo F, Yang CF, Eickhoff M, Esser MT, Tang RS, Dubovsky F.

PLoS One. 2013 Oct 29;8(10):e77104. doi: 10.1371/journal.pone.0077104. eCollection 2013.


Translational sciences approach to RSV vaccine development.

Kurzweil V, Tang R, Galinski M, Wang K, Zuo F, Cherukuri A, Gasser RA Jr, Malkin E, Sifakis F, Mendel DB, Esser MT.

Expert Rev Vaccines. 2013 Sep;12(9):1047-60. doi: 10.1586/14760584.2013.824706. Review.


HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.

Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Pinto LA, Gonzalez P, Wentzensen N, Esser MT, Matys K, Meuree A, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Safaeian M; Costa Rican Vaccine Trial Group.

PLoS One. 2013;8(1):e53067. doi: 10.1371/journal.pone.0053067. Epub 2013 Jan 2.


Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein.

Cherukuri A, Patton K, Gasser RA Jr, Zuo F, Woo J, Esser MT, Tang RS.

Clin Vaccine Immunol. 2013 Feb;20(2):239-47. doi: 10.1128/CVI.00580-12. Epub 2012 Dec 12.


Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women.

Ji J, Sun HK, Smith JS, Wang H, Esser MT, Hu S, Pretorius RG, Chen W, Belinson JL, Qiao YL.

BMC Infect Dis. 2012 Jun 20;12:137. doi: 10.1186/1471-2334-12-137.


Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.

Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, Radley DR, Esser MT, Weinberg A; IMPAACT P1047 Protocol Team.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):197-204. doi: 10.1097/QAI.0b013e3181de8d26.


Multiplexed serologic assay for nine anogenital human papillomavirus types.

Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT.

Clin Vaccine Immunol. 2010 May;17(5):818-27. doi: 10.1128/CVI.00348-09. Epub 2010 Mar 17.


Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A.

Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.


The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24.

Majewski S, Bosch FX, Dillner J, Iversen OE, Kjaer SK, Muñoz N, Olsson SE, Paavonen J, Sigurdsson K, Bryan J, Esser MT, Giacoletti K, James M, Taddeo F, Vuocolo S, Barr E.

J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1147-55. doi: 10.1111/j.1468-3083.2009.03266.x. Epub 2009 Apr 23.


Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigen.

Raedler MD, Heyne S, Wagner E, Shalkowski SK, Secore S, Anderson AS, Cook J, Cope L, McNeely T, Retzlaff M, Shanter J, Rubinstein LJ, Green T, Kartsonis N, Esser MT.

Clin Vaccine Immunol. 2009 May;16(5):739-48. doi: 10.1128/CVI.00478-08. Epub 2009 Mar 25.


An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.

Joyce JG, Krauss IJ, Song HC, Opalka DW, Grimm KM, Nahas DD, Esser MT, Hrin R, Feng M, Dudkin VY, Chastain M, Shiver JW, Danishefsky SJ.

Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15684-9. doi: 10.1073/pnas.0807837105. Epub 2008 Oct 6.


Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia.

Newall AT, Brotherton JM, Quinn HE, McIntyre PB, Backhouse J, Gilbert L, Esser MT, Erick J, Bryan J, Formica N, MacIntyre CR.

Clin Infect Dis. 2008 Jun 1;46(11):1647-55. doi: 10.1086/587895. Erratum in: Clin Infect Dis. 2008 Jul 15;47(2):302.


Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.

Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT.

Hum Vaccin. 2008 Mar-Apr;4(2):134-42. Epub 2007 Nov 4. Erratum in: Hum Vaccin. 2013 Apr;9(4):938.


Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women.

Perez G, Lazcano-Ponce E, Hernandez-Avila M, García PJ, Muñoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, Vuocolo S, Sattler C, Barr E.

Int J Cancer. 2008 Mar 15;122(6):1311-8.


Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.

Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E.

J Infect Dis. 2007 Oct 15;196(8):1153-62. Epub 2007 Sep 17.


Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics.

Skjeldestad FE, Mehta V, Sings HL, Øvreness T, Turpin J, Su L, Boerckel P, Roberts C, Bryan J, Jansen KU, Esser MT, Liaw KL.

Acta Obstet Gynecol Scand. 2008;87(1):81-8.


Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT.

Hum Vaccin. 2007 Jul-Aug;3(4):109-15. Epub 2007 Feb 24.


Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.

Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J.

Lancet. 2007 May 19;369(9574):1693-702.


Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.

Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E.

Vaccine. 2007 Jun 21;25(26):4931-9. Epub 2007 Apr 20.


Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators.

N Engl J Med. 2007 May 10;356(19):1928-43.


Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E.

Pediatr Infect Dis J. 2007 Mar;26(3):201-9.


Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.

Garland SM, Steben M, Hernandez-Avila M, Koutsky LA, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Esser MT, Vuocolo SC, Nelson M, Railkar R, Sattler C, Barr E; 012 Study Investigators.

Clin Vaccine Immunol. 2007 Jun;14(6):792-5. Epub 2007 Apr 11.


High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E.

Br J Cancer. 2006 Dec 4;95(11):1459-66. Epub 2006 Nov 21.


Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E.

Vaccine. 2006 Jul 7;24(27-28):5571-83. Epub 2006 May 15.


Supplemental Content

Loading ...
Support Center